Xaira Therapeutics vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 56)
Xaira Therapeutics logo

Xaira Therapeutics

ChallengerHealthcare & Life Sciences

AI Drug Discovery

AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.

AI VisibilityBeta
Overall Score
C56
Category Rank
#166 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
61
Perplexity
62
Gemini
51

About

Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

56
Overall Score
90
#166
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
61
ChatGPT
92
62
Perplexity
93
51
Gemini
89
55
Claude
96
57
Grok
95

Key Details

Category
AI Drug Discovery
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Xaira Therapeutics
AI Drug Discovery

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.